New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
05:16 EDTANACAnacor announces first patient enrolled in Phase 3 Trial of AN2728
Anacor Pharmaceuticals announced that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4, or PDE-4, inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10%-20% of infants and young children. The Phase 3 trial consists of two multi-center, double-blind, vehicle-controlled studies which will enroll approximately 750 subjects per study who will be randomized 2:1. Subjects who complete either Phase 3 study will have the option to enroll in a long-term safety trial to evaluate the safety of intermittent use of AN2728 Ointment, 2% for up to 12 months. At least 100 subjects will be enrolled for 12 months and at least 300 subjects will be enrolled for 6 months, during which time subjects will be treated as needed under the direction of the investigator.
News For ANAC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
07:40 EDTANACAnacor price target raised to $80 from $70 at Jefferies
Jefferies analyst David Steinberg raised his price target for Anacor Pharmaceuticals to $80 from $70 saying Kerydin continues to exceed expectations. Sandoz has now fully completed its planned sales force expansion for the toenail fungus treatment, Steinberg tells investors in a research note, citing his industry contacts. Further, pivotal AN2728 Phase 3 data is expected in the coming weeks, the analyst points out. He ascribes 80% odds to a positive readout for the atopic dermatitis candidate, which he feels could push the shares past $100. Steinberg keeps a Buy rating on Anacor.
June 30, 2015
09:15 EDTANACAnacor price target raised to $85 from $72 at Wedbush
Wedbush believes that sales of Anacor's Kerydin drug have been impressive and could cause the company's Q2 results to beat expectations. The firm significantly raised its 2015-2017 Kerydin sales estimates and keeps an Outperform rating on Anacor.
June 29, 2015
08:35 EDTANACAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use